455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
Reports Second Quarter 2025 Financial Results
Announces Pricing of $100 Million Public Offering
Other Events
Phase 2b REZOLVE - AD Topline Results from 16 - Week Induction Rezpegaldesleukin in Patients with Moderate - to - Severe Atopic Dermatitis June 24, 2025
Amendments to Articles of Incorporation or Bylaws
Shareholder votes
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities